Patients with Risk Factors for Complications Do Not Require Longer Antimicrobial Therapy for Complicated Intra-Abdominal Infection.
A prospective, multicenter, randomized controlled trial found that four days of antibiotics for source-controlled complicated intra-abdominal infection resulted in similar outcomes when compared with a longer duration. We hypothesized that patients with specific risk factors for complications also had similar outcomes. Short-course patients with obesity, diabetes, or Acute Physiology and Chronic Health Evaluation II ≥15 from the STOP-IT trial were compared with longer duration patients. Outcomes included incidence of and days to infectious complications, mortality, and length of stay. Obese and diabetic patients had similar incidences of and days to surgical site infection, recurrent intra-abdominal infection, extra-abdominal infection, and Clostridium difficile infection. Short- and long-course patients had similar incidences of complications among patients with Acute Physiology and Chronic Health Evaluation II ≥15. However, there were fewer days to the diagnosis of surgical site infection (9.5 ± 3.4 vs 21.6 ± 6.2, P = 0.010) and extra-abdominal infection (12.4 ± 6.9 vs 21.8 ± 6.1, P = 0.029) in the short-course group. Mortality and length of stay was similar for all groups. A short course of antibiotics in complicated intra-abdominal infection with source control seems to have similar outcomes to a longer course in patients with diabetes, obesity, or increased severity of illness.
University of Miami Miller School of Medicine, Miami, Florida, USA.
Rishi
R
Rattan
Casey J
CJ
Allen
Robert G
RG
Sawyer
John
J
Mazuski
Therese M
TM
Duane
Reza
R
Askari
Kaysie L
KL
Banton
Jeffrey A
JA
Claridge
Raul
R
Coimbra
Joseph
J
Cuschieri
E Patchen
EP
Dellinger
Heather L
HL
Evans
Christopher A
CA
Guidry
Preston R
PR
Miller
Patrick J
PJ
O'Neill
Ori D
OD
Rotstein
Michaela A
MA
West
Kimberley
K
Popovsky
Nicholas
N
Namias
D018806:APACHE; D000328:Adult; D000368:Aged; D000900:Anti-Bacterial Agents / Q000008:administration & dosage* / Q000627:therapeutic use; D048909:Diabetes Complications / Q000188:drug therapy* / Q000453:epidemiology / Q000209:etiology; D004334:Drug Administration Schedule; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D015994:Incidence; D057194:Intention to Treat Analysis; D059413:Intraabdominal Infections / Q000188:drug therapy* / Q000453:epidemiology / Q000209:etiology; D008297:Male; D008875:Middle Aged; D009765:Obesity / Q000150:complications*; D011446:Prospective Studies; D012307:Risk Factors; D013530:Surgical Wound Infection / Q000188:drug therapy* / Q000453:epidemiology / Q000209:etiology
D000900:Anti-Bacterial Agents